CN101970426A - 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂 - Google Patents

吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂 Download PDF

Info

Publication number
CN101970426A
CN101970426A CN2008801272472A CN200880127247A CN101970426A CN 101970426 A CN101970426 A CN 101970426A CN 2008801272472 A CN2008801272472 A CN 2008801272472A CN 200880127247 A CN200880127247 A CN 200880127247A CN 101970426 A CN101970426 A CN 101970426A
Authority
CN
China
Prior art keywords
alkyl
group
optionally substituted
phenyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801272472A
Other languages
English (en)
Chinese (zh)
Inventor
H·W·鲍尔斯
B·T·弗里斯特
R·劳弗
M·菲赫尔
P·B·桑普森
潘国华
S-W·李
刘勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN101970426A publication Critical patent/CN101970426A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2008801272472A 2007-12-21 2008-12-19 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂 Pending CN101970426A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US886507P 2007-12-21 2007-12-21
US61/008,865 2007-12-21
US13171708P 2008-06-11 2008-06-11
US61/131,717 2008-06-11
PCT/CA2008/002227 WO2009079767A1 (en) 2007-12-21 2008-12-19 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN101970426A true CN101970426A (zh) 2011-02-09

Family

ID=40800609

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801272472A Pending CN101970426A (zh) 2007-12-21 2008-12-19 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂

Country Status (7)

Country Link
US (1) US8765748B2 (https=)
EP (1) EP2235004A4 (https=)
JP (1) JP2011506494A (https=)
CN (1) CN101970426A (https=)
AU (1) AU2008340991B2 (https=)
CA (1) CA2709536C (https=)
WO (1) WO2009079767A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006642A (zh) * 2013-01-04 2013-04-03 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
CN106916143A (zh) * 2017-03-14 2017-07-04 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
WO2022184049A1 (zh) * 2021-03-02 2022-09-09 上海齐鲁制药研究中心有限公司 Plk4抑制剂及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
JP5629752B2 (ja) * 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
CN102295640B (zh) * 2011-06-29 2013-09-18 南京工业大学 3-杂环席夫碱-5-氟-吲哚-2-酮类化合物及其制备方法和应用
MX2016003892A (es) 2013-10-04 2016-06-17 Bayer Cropscience Ag Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
SG11201602882VA (en) 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
RS58413B1 (sr) 2013-10-18 2019-04-30 Univ Health Network So i kristalni oblici inhibitora plk-4
WO2015164956A1 (en) * 2014-04-29 2015-11-05 The University Of British Columbia Benzisothiazole derivative compounds as therapeutics and methods for their use
HUE057289T2 (hu) 2016-08-31 2022-05-28 Jiangsu Hengrui Medicine Co Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
SG11202111003UA (en) 2019-04-24 2021-11-29 Univ Health Network Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
ES3022196A1 (es) * 2023-11-27 2025-05-28 Univ Madrid Complutense Derivados de 2-indolinona y usos de los mismos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008202A2 (en) * 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
WO2004026829A2 (de) * 2002-09-12 2004-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
WO2005058309A1 (en) * 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1326A (en) * 1839-09-17 Improvement in the mode of setting and arranging sugar-kettles
DE3310891A1 (de) * 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1998007695A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
AU3770000A (en) 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
US7205328B2 (en) * 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
US20070135509A1 (en) * 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
WO2008152014A2 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
JP5629752B2 (ja) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008202A2 (en) * 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
WO2004026829A2 (de) * 2002-09-12 2004-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
WO2005058309A1 (en) * 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006642A (zh) * 2013-01-04 2013-04-03 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
CN103006642B (zh) * 2013-01-04 2014-10-22 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
CN106916143A (zh) * 2017-03-14 2017-07-04 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
WO2022184049A1 (zh) * 2021-03-02 2022-09-09 上海齐鲁制药研究中心有限公司 Plk4抑制剂及其用途
CN116964046A (zh) * 2021-03-02 2023-10-27 上海齐鲁制药研究中心有限公司 Plk4抑制剂及其用途
CN116964046B (zh) * 2021-03-02 2024-04-19 上海齐鲁制药研究中心有限公司 Plk4抑制剂及其用途

Also Published As

Publication number Publication date
CA2709536C (en) 2016-05-31
AU2008340991A1 (en) 2009-07-02
EP2235004A4 (en) 2011-05-04
US8765748B2 (en) 2014-07-01
WO2009079767A9 (en) 2009-10-01
EP2235004A1 (en) 2010-10-06
AU2008340991B2 (en) 2012-02-23
WO2009079767A1 (en) 2009-07-02
CA2709536A1 (en) 2009-07-02
JP2011506494A (ja) 2011-03-03
US20110065702A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
CN101970426A (zh) 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂
USRE47731E1 (en) Kinase inhibitors and method of treating cancer with same
US10358436B2 (en) Kinase inhibitors and method of treating cancer
CN105102453B (zh) 作为布罗莫结构域抑制剂的苯并咪唑酮衍生物
CN116723843A (zh) 用于治疗和/或预防癌症的sos1抑制剂的药物组合
CN115960105A (zh) Kras g12d抑制剂及其在医药上的应用
WO2016026445A1 (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
WO2013064068A1 (zh) 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
JP6057907B2 (ja) チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN109641908B (zh) 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN107074812A (zh) 新型取代的嘧啶化合物
CN103214480B (zh) 吡唑并吡啶炔苯类化合物及其药用组合物和应用
CN101166719A (zh) Bcrp/abcg2抑制剂
TW200400965A (en) Antiviral compounds
WO2022028556A1 (zh) Cdk9抑制剂及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110209